Discontinued — last reported Q1 '26
Zerbaxa — Sales
Merck & Co. Zerbaxa — Sales decreased by 52.9% to $82.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 41.4%, from $140.00M to $82.00M. Over 3 years (FY 2022 to FY 2025), Zerbaxa — Sales shows an upward trend with a 22.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand and successful commercial execution, while a decrease may signal market saturation, competitive pressure, or patent-related headwinds.
Detailed definition
This metric represents the total gross revenue generated from the sale of the specific pharmaceutical product line durin...
Peer comparison
Standard revenue reporting for specific drug franchises; comparable to 'product revenue' or 'net sales' reported by other pharmaceutical companies for their key therapeutic assets.
mrk_segment_zerbaxa_salesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$2.00M | -$4.00M | $60.00M | $92.00M | $86.00M | $99.00M | $100.00M | $108.00M | $106.00M | $123.00M | $112.00M | $123.00M | $129.00M | $140.00M | $140.00M | $148.00M | $162.00M | $174.00M | $82.00M |
| QoQ Change | — | -100.0% | >999% | +53.3% | -6.5% | +15.1% | +1.0% | +8.0% | -1.9% | +16.0% | -8.9% | +9.8% | +4.9% | +8.5% | +0.0% | +5.7% | +9.5% | +7.4% | -52.9% |
| YoY Change | — | — | — | >999% | >999% | — | +66.7% | +17.4% | +23.3% | +24.2% | +12.0% | +13.9% | +21.7% | +13.8% | +25.0% | +20.3% | +25.6% | +24.3% | -41.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s zerbaxa — sales?
- Merck & Co. (MRK) reported zerbaxa — sales of $82.00M in Q1 2026.
- How has Merck & Co.'s zerbaxa — sales changed year-over-year?
- Merck & Co.'s zerbaxa — sales decreased by 41.4% year-over-year, from $140.00M to $82.00M.
- What is the long-term trend for Merck & Co.'s zerbaxa — sales?
- Over 3 years (2022 to 2025), Merck & Co.'s zerbaxa — sales has grown at a 22.8% compound annual growth rate (CAGR), from $337.00M to $624.00M.
- What does zerbaxa — sales mean?
- The total revenue generated from the sales of this specific product line.